



1 May 2020

ASX ANNOUNCEMENT

NOTICE UNDER SECTION 708A OF THE CORPORATIONS ACT

This notice is given by Cynata Therapeutics Limited pursuant to section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Act**).

The Company has today issued 569,251 fully paid ordinary shares at an issue price of \$0.60 per share (**Shares**) in accordance with the terms of a placement to institutional investors announced to ASX on 22 April 2020 and the Company's Appendix 2A announced to the ASX on 24 April 2020 (**Placement**).

Pursuant to paragraph 708A(5)(e) of the Act, the Company gives notice that:

1. the Company issued the Shares without disclosure to investors under Part 6D.2 of the Act;
2. as at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
 - (b) section 674 of the Act; and
3. as at the date of this notice, there is no information that is "excluded information" (as defined in section 708A(7) of the Act) which is required to be disclosed by the Company.

As announced to ASX on 17 April and 22 April 2020, Cynata is in active discussions about a potential clinical trial in indications consequent to severe COVID-19 infection. These discussions, which are being held with the relevant regulatory and other bodies, are continuing. There is no guarantee that a clinical trial in indications consequent to severe COVID-19 infection will be approved.

Authorised by

A handwritten signature in black ink, appearing to read "Peter Webse".

Peter Webse
Company Secretary